Humanigen, Inc. (HGEN) Starts Presentation at LD Micro Virtual Event
Humanigen (OTCQB: HGEN) is a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company’s focus is on making chimeric antigen receptor T-cell (CAR-T) therapy safer, better and more routine. CAR-T therapy uses a patient’s immune system to recognize and attack a specific tumor antigen. Clinical trials have shown high remission rates, including remission in radiation- and chemo-unresponsive patients but at high risk. The company is working to reduce these risks and improve the efficacy of CAR-T therapies. For more information, visit the company’s website at www.humanigen.com. About NetworkNewsWire NetworkNewsWire (NNW) is…







